Study to Provide Continued Access to Treatment for Patients Completing a Previous Trial With Efanesoctocog Alfa

NCT06716814 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

104

Enrollment

INDUSTRY

Sponsor class

Conditions

Haemophilia A (Moderate or Severe)

Interventions

DRUG: Efanesoctocog alfa

Sponsor

Swedish Orphan Biovitrum

Collaborators

[object Object]